drug · small molecule
patient view →dexmedetomidine
Marketedupdated 2mo agoby $BTAI BioXcel Therapeutics, Inc.🔗 ChEMBL
Approvedcommunity read0 votes
Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for irritability and 84 investigational indications.
indications
investigational
Schizophrenia
targets
Adrenergic receptor alpha-2
all catalysts(18)
approval · 3
phase 0 trial completion · 7
phase 2 3 completion · 1
phase 2 completion · 6
phase 2 initiation · 1
News(0)
no news has mentioned this drug yet
comments(0)
5-min edit window · permanent after that